This is a preview of subscription content, access via your institution.
Literatur
- 1.
Hodos RA, Kidd BA, Shameer K et al (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8:186–210
- 2.
Schüler J (2016) Die Biotechnologie-Industrie Ein Einführungs‑, Übersichtsund Nachschlagewerk. Springer Spektrum, Berlin Heidelberg
- 3.
Knobloch J, Jungck D, Koch A (2017) The molecular mechanisms of thalidomide teratogenicity and implications for modern medicine. Curr Mol Med 17:108–117
- 4.
Miro-Canturri A, Ayerbe-Algaba R, Smani Y (2019) Drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol 10:41
- 5.
Zheng W, Sun W, Simeonov A (2018) Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol 175:181–191
- 6.
Anonymous (2018) Hamburg setzt auf neue Initiative für rationalen Antibiotikaeinsatz. Deutsches Ärzteblatt 19. April
- 7.
Tulbah AS, Ong HX, Morgan L et al (2015) Dry powder formulation of simvastatin. Expert Opin Drug Deliv 12:857–868
- 8.
Pallotta MT, Tascini G, Crispoldi R et al (2019) Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med 17:238
- 9.
Bissler JJ, Kingswood JC, Radzikowska E et al (2017) Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST‑2 study. PLoS ONE 12:e180939
- 10.
Zanin M, Chorbev I, Stres B et al (2019) Community effort endorsing multiscale modelling, multiscale data science and multiscale computing for systems medicine. Brief Bioinformatics 20:1057–1062
- 11.
Sun P, Guo J, Winnenburg R et al (2017) Drug repurposing by integrated literature mining and drug-gene-disease triangulation. Drug Discov Today 22:615–619
- 12.
Liu Z, Fang H, Reagan K et al (2013) In silico drug repositioning: what we need to know. Drug Discov Today 18:110–115
- 13.
Jin G, Wong ST (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19:637–644
- 14.
Agrawal S, Vamadevan P, Mazibuko N et al (2019) A new method for ethical and efficient evidence generation for off-label medication use in oncology (A case study in Glioblastoma). Front Pharmacol 10:681
- 15.
Burton M (2019) “Repurposing” off-patent drugs offers big hopes of new treatments. Economist. https://www.economist.com/international/2019/02/28/repurposing-off-patent-drugs-offers-big-hopes-of-new-treatments
- 16.
Katsanos K, Spiliopoulos S, Kitrou P et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 7:e11245
- 17.
Busch A, Chernogubova E, Jin H et al (2018) Four surgical modifications to the classic elastase perfusion aneurysm model enable haemodynamic alterations and extended elastase perfusion. Eur J Vasc Endovas Surg. https://doi.org/10.1016/j.ejvs.2018.03.018
- 18.
Simon F, Oberhuber A (2016) Ischemia and reperfusion injury of the spinal cord: experimental strategies to examine postischemic paraplegia. Neural Regen Res 11:414–415
- 19.
Eitenmuller I, Volger O, Kluge A et al (2006) The range of adaptation by collateral vessels after femoral artery occlusion. Circulation Research 99:656–662
- 20.
Simon FH, Erhart P, Vcelar B et al (2016) Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model. J Vasc Surg 64:1797–1804
- 21.
Van Goor F, Straley KS, Cao D et al (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290:L1117–L1130
- 22.
Donaldson SH, Pilewski JM, Griese M et al (2018) Tezacaftor/Ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med 197:214–224
- 23.
Hwang TC, Yeh JT, Zhang J et al (2018) Structural mechanisms of CFTR function and dysfunction. J Gen Physiol 150:539–570
- 24.
Kuhnl A, Erk A, Trenner M et al (2017) Incidence, treatment and mortality in patients with abdominal aortic aneurysms. Dtsch Arztebl Int 114:391–398
- 25.
Trickett JP, Scott RA, Tilney HS (2002) Screening and management of asymptomatic popliteal aneurysms. J Med Screen 9:92–93
- 26.
Jin H, Li DY, Chernogubova E et al (2018) Local delivery of miR-21 stabilizes fibrous caps in vulnerable atherosclerotic lesions. Mol Ther 26:1040–1055
- 27.
Wang D, Deuse T, Stubbendorff M et al (2015) Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol 35:1945–1953
- 28.
Golledge J, Moxon J, Pinchbeck J et al (2017) Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg 104:1486–1493
- 29.
Fujimura N, Xiong J, Kettler EB et al (2016) Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg 64:46–54e8
- 30.
Villoutreix BO, Lagorce D, Labbe CM et al (2013) One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov Today 18:1081–1089
Author information
Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Forstner, W. Eilenberg, F. Simon, M. Trenner, H.H. Eckstein, L. Maegdefessel und A. Busch geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Forstner, M., Eilenberg, W., Simon, F. et al. „Drug repurposing“ und „orphan drug usage“. Gefässchirurgie 24, 564–567 (2019). https://doi.org/10.1007/s00772-019-00573-8
Published:
Issue Date: